A first-in-human phase I study of BKM120, an oral pan-class I PI3K inhibitor, in patients (pts) with advanced solid tumors.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 3003-3003 ◽  
Author(s):  
J. Baselga ◽  
M. J. De Jonge ◽  
J. Rodon ◽  
H. A. Burris ◽  
D. C. Birle ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Pi3k Inhibitor ◽  
Class I ◽  
Advanced Solid Tumors

scholarly journals Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245408 (XL147), an Oral Pan-Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

2013 ◽  
Vol 20 (1) ◽  
pp. 233-245 ◽  
Author(s):  
Geoffrey I. Shapiro ◽  
Jordi Rodon ◽  
Cynthia Bedell ◽  
Eunice L. Kwak ◽  
Jose Baselga ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Pi3k Inhibitor ◽  
Class I ◽  
Advanced Solid Tumors ◽  
Pharmacodynamic Study

First-in-human phase I study of the oral PI3K inhibitor BEZ235 in patients (pts) with advanced solid tumors.

2010 ◽  
Vol 28 (15_suppl) ◽  
pp. 3005-3005 ◽  
Author(s):  
H. Burris ◽  
J. Rodon ◽  
S. Sharma ◽  
R. S. Herbst ◽  
J. Tabernero ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Pi3k Inhibitor ◽  
Advanced Solid Tumors

A first-in-human phase I study of intravenous PI3K inhibitor BAY 80-6946 in patients with advanced solid tumors: Results of dose-escalation phase.

2011 ◽  
Vol 29 (15_suppl) ◽  
pp. 3035-3035 ◽  
Author(s):  
A. Patnaik ◽  
L. J. Appleman ◽  
J. M. Mountz ◽  
R. K. Ramanathan ◽  
M. Beeram ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Phase I Study ◽  
Pi3k Inhibitor ◽  
Advanced Solid Tumors

Phase I dose-escalation and -expansion study of buparlisib (BKM120), an oral pan-Class I PI3K inhibitor, in patients with advanced solid tumors

2014 ◽  
Vol 32 (4) ◽  
pp. 670-681 ◽  
Author(s):  
Jordi Rodon ◽  
Irene Braña ◽  
Lillian L Siu ◽  
Maja J De Jonge ◽  
Natasha Homji ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Dose Escalation ◽  
Pi3k Inhibitor ◽  
Class I ◽  
Advanced Solid Tumors

scholarly journals Phase I study of alpelisib (BYL719), an α-specific PI3K inhibitor, in Japanese patients with advanced solid tumors

2019 ◽  
Vol 110 (3) ◽  
pp. 1021-1031 ◽  
Author(s):  
Yuichi Ando ◽  
Satoru Iwasa ◽  
Shunji Takahashi ◽  
Hideo Saka ◽  
Tomoyuki Kakizume ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Study ◽  
Japanese Patients ◽  
Pi3k Inhibitor ◽  
Advanced Solid Tumors

scholarly journals Phase I Trial of a Tablet Formulation of Pilaralisib, a Pan‐Class I PI3K Inhibitor, in Patients with Advanced Solid Tumors

2018 ◽  
Vol 23 (4) ◽  
pp. 401 ◽  
Author(s):  
Gerald Edelman ◽  
Jordi Rodon ◽  
Joanne Lager ◽  
Christelle Castell ◽  
Jason Jiang ◽  
...  
Keyword(s):  
Phase I ◽  
Solid Tumors ◽  
Phase I Trial ◽  
Tablet Formulation ◽  
Pi3k Inhibitor ◽  
Class I ◽  
Advanced Solid Tumors
Sign in / Sign up

Export Citation Format

Share Document